Abstract
The efficacy and safety of nanosomal paclitaxel lipid suspension [NPLS; 175 and 80 mg/m2 every 3-weekly (Q3W) and weekly (QW)] versus conventional paclitaxel (175 mg/m2 Q3W) in metastatic breast cancer (MBC) patients has been established in a previous phase II/III study. The current extension study presents the updated data of 174 patients (main study: N=120; extended study: N=54).
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Annals of oncology : official journal of the European Society for Medical Oncology
Paper Title
Journal
Date
